NEURODEGENERATION - ALS PROGRAM

Novation Pharmaceuticals is focused on changing the death sentence for ALS; its first indication in the neurodegeneration/dementia therapeutic area. Targeting messenger RNA (mRNA) using small molecules that can restore stress granules in ALS patients back to normal physiological levels, Novation's goal is to bring an effective therapeutic quickly to market. No cure or effective disease modifying treatment exists for the sporadic form of the disease which represents 95% of patients.

Novation is advancing its ALS program in collaboration with researchers at the University of Montreal and IRCM, Montreal.

A NEW PARADIGM IN SMALL-MOLECULE DRUG DISCOVERY

Novation Pharmaceuticals' approach is to identify new small-molecules, that modulate intracellular mRNA, to find new therapies to treat serious diseases. Novation's technology, called QUEST, is a breakthrough in identifying new, orally active small molecule drugs for significant therapeutic targets.
Novation is seeking to build a product focused business based on modulation of mRNA. Priority is to discover its own products using QUEST, whilst generating early revenues through strategic partnerships with pharmaceutical companies.

Novation's QUEST technology -- taking drug discovery to a new level